新浪登录
腾讯登录Bayer扩大研究合作，开展心血管新药研发
| 导读 | Bayer HealthCare今天宣布与美国布罗德研究所扩大了原有的双边合作，共同开展包括心血管基因组科学在内的多种疾病药物研发。 |
Bayer HealthCare今天宣布与美国布罗德研究所扩大了原有的双边合作，共同开展包括心血管基因组科学在内的多种疾病药物研发。
Bayer在声明中表示，作为合作协议的一部分，Bayer与布罗德研究所将在致病基因的发现、药物靶点的确认与药物药理等方面展开合作。来自两机构的联合指导委员会和联合研究委员会将对研究进展与研究方向进行监管。金融和其他交易条款没有在声明披露。
今天的扩大协议在某种程度上可以作为两个机构在2013年九月所签订协议的补充，促进两机构合作发现与开发针对多样性癌症基因组的治疗手段。Bayer表示诸如吸烟、饮食嗜好与运动状况在内的多种生活方式都会成为引起心脏病的罪魁祸首，遗传因素则会影响心血管疾病的易感性,发病的年龄以及严重程度。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：
NEW YORK (GenomeWeb) - Bayer HealthCare today announced it has expanded a drug development collaboration with the Broad Institute to include cardiovascular genomics.
As part of the expanded deal, Bayer and the Broad will collaborate on genetic discovery, target identification, and drug discovery activities. A joint steering committee and joint research committee will oversee research progress and direction, Bayer said. Financial and other terms of the deal were not disclosed.
The deal expands an agreement reached by the partners in September 2013 to discover and develop therapeutic agents targeting cancer genome alterations.
Bayer said that while lifestyle factors, such as smoking, diet, and exercise, are the main culprits behind heart disease, genetic factors can influence the predisposition to cardiovascular disease, the age of onset, and severity.
还没有人评论，赶快抢个沙发